NCT01701089View on ClinicalTrials.gov

A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy Volunteer, Alzheimer's Disease
Interventions
DRUG

11C-L-deprenyl-D2

Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total

DRUG

RO4602522

Multiple doses of RO4602522 for 14 days

DRUG

RO4602522

Multiple doses of RO4602522 for up to 17 days

Trial Locations (1)

141 86

Stockholm

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01701089 - A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers | Biotech Hunter | Biotech Hunter